---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-056179"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T09:46:56.831235+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma reports positive Phase 1b/2a results for ATYR1923; Q3 cash $116.4M

## Summary
- Positive proof-of-concept data for ATYR1923 in pulmonary sarcoidosis; registrational trial expected in 2022.
- Cash, cash equivalents and investments $116.4M at Sept 30, 2021, after $80.6M net from stock offering.
- R&D expenses $5.1M and G&A $2.6M for Q3 2021; 27.8M shares outstanding.
- Appointed Robert W. Ashworth, PhD, as VP of Regulatory Affairs.

## SEC filing metadata
- accession: 0001564590-21-056179
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000156459021056179/0001564590-21-056179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000156459021056179/life-8k_20211110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-056179
- JSON: https://secwatch.observer/filing/0001564590-21-056179.json
- Plain text: https://secwatch.observer/filing/0001564590-21-056179.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.